文献速递流行病学与生物统计临床试验与 GCP

他汀类药物产品标签中不良反应的评估:双盲随机对照试验的荟萃分析

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
PubMed 文献 · Lancet · 2026-02-05

该研究基于19项双盲随机对照试验的个体参与者数据,评估他汀产品标签中列出的不良结局。结果显示,除肌肉结局和糖尿病外,66种其他不良结局中仅4种具有统计学显著性。作者认为标签中多数不良事件与他汀的因果关系缺乏随机试验证据支持。

要点

  • 双盲随机试验数据不支持他汀与认知障碍、抑郁、睡眠障碍及周围神经病变的因果关系。
  • 仅肝转氨酶异常、其他肝功能异常、尿成分改变和水肿在FDR校正后显著。
  • 肝转氨酶异常在强化他汀治疗中亦显著,提示剂量依赖效应。

核心结论

  • 双盲随机试验的不良事件数据不支持他汀治疗与产品标签中多数病症(包括认知障碍、抑郁、睡眠障碍和周围神经病变)存在因果关系。

研究设计与样本

  • 研究为个体参与者数据的荟萃分析,纳入至少1000例参与者、预定治疗期至少2年、双盲比较他汀与安慰剂或强化与弱化他汀方案的随机试验。
  • 通过电子药物汇编检索五种他汀(阿托伐他汀、氟伐他汀、普伐他汀、瑞舒伐他汀和辛伐他汀)SmPC中列出的所有不良效应术语。

主要发现

  • 四项强化与弱化他汀方案试验亦发现肝转氨酶异常和其他肝功能检查异常显著超额(支持剂量依赖效应),但尿成分改变或水肿无显著超额。

关键数值与推荐

  • 统计显著性经错误发现率(FDR)控制在5%后评估。
  • 事件率比(RR)及95%CI用于比较他汀与安慰剂组的不良事件发生率。

临床怎么用

  • 临床医生可依据随机试验证据向患者解释他汀标签中多数不良反应缺乏因果关系证据。
  • 应关注肝转氨酶异常等有随机证据支持的不良反应,尤其强化他汀治疗时。
  • 支持修订产品标签及其他官方健康信息源,以促进患者和医生做出知情决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statin product labels (eg, Summaries of Product Characteristics [SmPCs]) list certain adverse outcomes as potential treatment-related effects based mainly on non-randomised and non-blinded studies, which might be subject to bias. We aimed to assess the evidence for such undesirable effects more reliably through a meta-analysis of individual participant data from large double-blind trials of statin therapy. METHODS: In this meta-analysis of individual participant-level data from double-blind randomised controlled trials, we generated a list of all undesirable effect terms listed in statin SmPCs by searching an electronic medicines compendium for five statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin). Randomised trials were eligible for meta-analysis of these effects if they involved at least 1000 participants, had a scheduled treatment period of at least 2 years, and involved a double-blind comparison of statin versus placebo or of a more intensive versus a less intensive statin regimen. Event rate ratios (RRs) and 95% CIs were calculated with statistical significance assessed after controlling the false discovery rate (FDR) at 5%. FINDINGS: 19 trials compared statin versus placebo (123 940 participants, median follow-up 4·5 years [IQR 3·1-5·4]). In addition to previously reported effects on muscle outcomes and diabetes, only four of 66 further undesirable outcomes that had been attributed to statins were FDR significant: abnormal liver transaminases (783 participants [0·30% per annum] allocated statin vs 556 [0·22% per annum] allocated placebo, RR 1·41 [95% CI 1·26-1·57]) and other liver function test abnormalities (651 participants [0·25% per annum] allocated statin vs 518 [0·20% per annum] allocated placebo, RR 1·26 [1·12-1·41]; absolute annual excess of 0·13% for combined liver function test abnormality), urinary composition alteration (556 [0·21% per annum] allocated statin vs 472 [0·18% per annum] allocated placebo, RR 1·18 [1·04-1·33]), and oedema (3495 [1·38% per annum] allocated statin vs 3299 [1·31% per annum] allocated placebo, RR 1·07 [1·02-1·12]). Analysis of the four trials of more intensive versus less intensive statin regimens also found significant excesses for abnormal liver transaminases and other liver function test abnormalities (supporting a dose-dependent effect), but no significant excess was found for urinary composition alteration or oedema. INTERPRETATION: Adverse event data from blinded randomised trials do not support causal relationships between statin therapy and most of the conditions (including cognitive impairment, depression, sleep disturbance, and peripheral neuropathy) listed in product labels as potential undesirable effects. In light of these findings, such labelling and other official sources of health information should be revised so that patients and their doctors can make appropriately informed decisions regarding statin therapy. FUNDING: British Heart Foundation, UK Medical Research Council, and Australian National Health and Medical Research Council.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet. 2026. PMID: 41655587. doi:10.1016/S0140-6736(25)01578-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。